Sickle Cell Disease

Central IRB #H-39846/ NHLB #SCD-CARRE: Sickle Cell Disease & CardiovAscular Risk – Red cell Exchange Trial

Central IRB #H-40856/ Forma #4202-HEM-301 (HIBISCUS): An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Agonist in Patients with Sickle Cell Disease (HIBISCUS)

Central IRB #H-42604/ Agios #AG348-C-020: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease (pending IRB approval)

Central IRB #H-41731/ Agios #AG946-C-001: A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Subjects with Sickle Cell Disease (not yet submitted to IRB)

Central IRB #H-42820/ GBT #GBT440-4R2: An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor) (not yet submitted to IRB)